公司报告 | 公司点评 麒盛科技（603610） 证券研究报告 越南工厂顺利投产 公司发布 24 年报及 25Q1 财报 25Q1 公司实现营收 7.9 亿元，同比+4%，显示公司业务保持稳定增长。归 母净利润为 0.4 亿元，同比微降 1%，扣非归母净利润为 0.5 亿元，同比下 降 7%。 24 年公司实现营收 30 亿同比-5%，归母净利为 1.6 亿同比-24%，扣非归母 净利 1.9 亿同比-25%。 分产品看，24 年智能电动床营收 24 亿元同比-5%，占比 84%；床垫营收 2.2 亿同比-7%，配件及其他营收 2.5 亿同比+3%。 分地区看，24 年公司境内营收 1.8 亿同比-18%，境外营收 27 亿同比-3%。 分销售模式看，24 年公司大宗业务营收 24 亿同比-4%，线上销售营收 4 亿 同比-8%，其他业务营收 0.3 亿同比-25%。 毛利率看，24 年公司家具制造毛利率 35.7%，同比-1.2pct；其中智能电动 床实现毛利率 34.3%，同比-1.1pct，床垫毛利率 42.0%同比-4.4pct，配件及 其他毛利率 43.2%同比+0.2pct。 拓展国内外新客户，保 ...

行业报告 | 行业研究周报 消费电子 证券研究报告 关税协议阶段性落地，看好消费电子板块修复机会 3D 打印：1）近期华工科技全资子公司华工激光拟与立铠精密成立合资公 司，重点突破 3D 增材 SLM 制造技术。2）设备供应商：与 3C 制造商的深 度协同，使民用消费品领域正成为布局重点。3）3D 打印产业链上游正迎 来关键的国产化突破阶段：国内产业链建设取得显著进展，铂力特、中航 迈特在金属材料，锐科激光在激光器等领域持续突破，有望打破国外技术垄 断。航空航天领域已解决技术可行性问题。 果链：1）iPhone16 系列当前在不同销售体系中已出现价格分层：目前苹 果官网与直营门店售价保持不变，授权门店则统一执行下调后的挂牌价， 而电商平台通过限时发券和补贴，将部分型号价格进一步压至 6000 元以 下，满足"以旧换新"补贴门槛。2）重视创新驱动： 苹果的首款折叠屏 iPhone 将采用类似书籍的折叠形式（即大折叠），而非翻盖式设计。该机型 在折叠状态下屏幕尺寸为 5.7 英寸，而在展开后屏幕尺寸将接近 8 英寸。采 用集成 Touch ID 的侧面按键。立讯精密凭借扎实的技术积累和稳定的量产 能力获得苹果等国 ...

证券研究报告 | 2025 年 05 月 22 日 晨会集萃 制作：产品中心 重点推荐 《策略|微观流动性跟踪(2025.5.5-2025.5.18)》 1、微观流动性整体：两融资金重新转为净流入，产业资本减持规模收窄。 本期资金供给合计-125 亿元，资金需求-32 亿元，整体对于市场净流出 93 亿元。1）两融资金重新转为净流入。本期两融表现为净流入 182.44 亿元，较上期的净流入-163.27 亿相比变化 345.71 亿；2）偏股型公募新 发份额有所下滑。本期偏股型公募新发份额为 108.35 亿份，相较于上期 259.31 亿份变化-58.22%。；3）产业资本净减持规模收窄。本期产业资本 表现为净减持 59.75 亿元（增持 36.96 亿元，减持 96.71 亿元），上期净减 持 67.99 亿元（增持 14.07 亿元，减持 82.07 亿元），本期大股东转为净减 持。2、五月增量政策逐步落地，央行先于美联储降息，同时中美贸易会 谈传来利好。从资金面来看，两融资金重新转为净流入，偏股型公募基金 新发份额超过百亿份，产业资本减持规模呈现收窄迹象，表明投资者信心 增加，而南向资金则转为净流出， ...

港股公司报告 | 首次覆盖报告 药师帮（09885） 证券研究报告 平台+自营+首推，数字化解决方案赋能全产业链 平台+自营+首推，院外数字化龙头首次扭亏为盈 药师帮成立于 2015 年，是中国院外医药产业最大的数字化综合服务平台。 公司持续聚焦与深耕院外医药市场，近年来已完成"平台+自营+首推"业 务模式的拓展，全面覆盖院外医药产业链布局。2019-2024 年，公司收入 规模持续增长，由 32.52 亿元增长至 179.04 亿元，cagr 为 40.66%。同时 2024 年公司实现净利润超 3001 万元，首次全面转正，经调净利润达 1.57 亿 元，同比增长 20.1%，标志着公司已经全面迈入持续正向的盈利新阶段。 平台业务：向上丰富药品供给，向下拓展终端，经营效率持续优化 公司的平台业务的卖家为上游药品经销商，买家主要为下游药店与基层医 疗机构。1）向上：公司持续巩固供应链能力，丰富药品 SKU 供给，截止 至 2024 年，公司平台月均 SKU 数已持续增长至超过 390 万个。2）向下： 加速下游买家拓展，连锁药店及基层医疗机构快速增长。截至 2024 年，公 司累计注册下游买家数超 82.7 ...

港股公司报告 | 首次覆盖报告 药师帮（09885） 证券研究报告 平台+自营+首推，数字化解决方案赋能全产业链 平台+自营+首推，院外数字化龙头首次扭亏为盈 药师帮成立于 2015 年，是中国院外医药产业最大的数字化综合服务平台。 公司持续聚焦与深耕院外医药市场，近年来已完成"平台+自营+首推"业 务模式的拓展，全面覆盖院外医药产业链布局。2019-2024 年，公司收入 规模持续增长，由 32.52 亿元增长至 179.04 亿元，cagr 为 40.66%。同时 2024 年公司实现净利润超 3001 万元，首次全面转正，经调净利润达 1.57 亿 元，同比增长 20.1%，标志着公司已经全面迈入持续正向的盈利新阶段。 平台业务：向上丰富药品供给，向下拓展终端，经营效率持续优化 公司的平台业务的卖家为上游药品经销商，买家主要为下游药店与基层医 疗机构。1）向上：公司持续巩固供应链能力，丰富药品 SKU 供给，截止 至 2024 年，公司平台月均 SKU 数已持续增长至超过 390 万个。2）向下： 加速下游买家拓展，连锁药店及基层医疗机构快速增长。截至 2024 年，公 司累计注册下游买家数超 82.7 ...

Investment Rating - The investment rating for Alibaba-W (09988) is "Buy" with a target price set for the next six months [5][13]. Core Insights - Alibaba's revenue for FY25Q4 reached 236.5 billion yuan, with adjusted EBITDA of 41.8 billion yuan and a net profit of 30 billion yuan, indicating strong performance across its business segments [1]. - The Taobao Tmall Group generated 101.4 billion yuan in revenue, exceeding Bloomberg's consensus by 3.6%, driven by a 12% year-on-year increase in customer management revenue due to improved take rates [2]. - The cloud business reported 30.1 billion yuan in revenue, with an 18% year-on-year growth, primarily due to the rapid adoption of AI-related products, which have maintained triple-digit year-on-year growth for seven consecutive quarters [2]. - The AIDC segment achieved 33.6 billion yuan in revenue, with a 22% year-on-year increase, supported by strong cross-border business performance [3]. - Shareholder returns included a buyback of 6 billion USD for 51 million shares in FY25, and a total of 11.97 billion shares repurchased for 11.9 billion USD, resulting in a net reduction of 995 million shares [4]. Summary by Sections Taobao Tmall Group - Revenue for FY25Q4 was 101.4 billion yuan, with adjusted EBITDA of 41.7 billion yuan. Customer management revenue increased by 12% year-on-year, benefiting from improved take rates and ongoing investments in user growth and service optimization [2]. Cloud Business - Revenue for FY25Q4 was 30.1 billion yuan, with adjusted EBITDA of 2.4 billion yuan. The cloud segment's revenue grew by 18% year-on-year, driven by the increasing adoption of AI products across various industries [2]. AIDC - Revenue for FY25Q4 was 33.6 billion yuan, with adjusted EBITDA of -3.6 billion yuan. The segment's revenue grew by 22% year-on-year, focusing on operational efficiency and strategic market expansion [3]. Other Businesses - Cainiao generated 21.6 billion yuan in revenue with adjusted EBITDA of -610 million yuan. Local life services reported 16.1 billion yuan in revenue with adjusted EBITDA of -2.3 billion yuan [3]. Shareholder Returns - In FY25, Alibaba repurchased shares worth 11.9 billion USD, leading to a net reduction in shares outstanding. The board approved a total dividend of 0.25 USD per share, amounting to approximately 4.6 billion USD [4]. Investment Outlook - The report anticipates revenue growth for FY 2026-2028 to be 1,035.3 billion, 1,105.7 billion, and 1,179.8 billion yuan respectively, with net profit projections of 180.7 billion, 185.9 billion, and 195.7 billion yuan [5].

Investment Rating - The investment rating for the company is upgraded to "Buy" [6][5]. Core Viewpoints - The company achieved a revenue of 1.077 billion yuan in 2024, representing a year-on-year growth of 46%, and a net profit of 128 million yuan, up 8.67% year-on-year. In Q1 2025, the company reported a revenue of 285 million yuan, a 55% increase year-on-year, and turned a profit with a net profit of 26 million yuan [1][2]. - The growth in revenue is attributed to improved industry conditions, optimized product structure, new customer mass production, and increased capacity utilization. Despite the net profit growth being lower than revenue growth due to rising costs, the company demonstrated solid cost control and profitability [2][4]. - The company is focusing on high-performance chip testing, including CPU, GPU, AI, and advanced packaging chips, with a revenue of 615 million yuan from wafer testing, up 38.91%, and 367 million yuan from finished chip testing, up 50.07% [3]. - The company plans to raise 1.175 billion yuan through convertible bonds to enhance its testing capabilities and increase revenue from high-end services [3]. - The customer base has expanded significantly, with over 200 clients established, leading to substantial growth in production and sales of wafer and finished chip testing [4]. Financial Data Summary - The company forecasts revenues of 1.369 billion yuan for 2025, 1.743 billion yuan for 2026, and 2.308 billion yuan for 2027, with respective growth rates of 27.14%, 27.34%, and 32.36% [5][11]. - The projected net profit for 2025 is 196 million yuan, increasing to 280 million yuan in 2026 and 387 million yuan in 2027, with growth rates of 52.78%, 42.90%, and 38.16% respectively [5][11]. - The company's EBITDA is expected to reach 618 million yuan in 2025, 690 million yuan in 2026, and 771 million yuan in 2027 [5][11]. - The company maintains a healthy financial position with a debt-to-asset ratio of 48.67% and a net asset value per share of 23.33 yuan [7][11].

Investment Rating - The investment rating for the company is upgraded to "Buy" based on the recovery in the semiconductor industry and changes in revenue structure [6][5]. Core Viewpoints - The company achieved a revenue of 1.077 billion yuan in 2024, representing a year-on-year growth of 46%, and a net profit of 128 million yuan, up 8.67% year-on-year. In Q1 2025, the company reported a revenue of 285 million yuan, a 55% increase year-on-year, and turned a profit with a net profit of 26 million yuan [1][2]. - The growth in revenue is attributed to improved industry conditions, optimized product structure, new customer mass production, and increased capacity utilization. Despite the net profit growth being lower than revenue growth, the company demonstrated solid cost control and profitability [2][4]. - The company is focusing on high-performance chip testing, including CPU, GPU, AI, and advanced packaging chips, with a significant increase in revenue from wafer testing (6.15 billion yuan, up 38.91%) and finished chip testing (3.67 billion yuan, up 50.07%) [3][4]. - The company plans to raise 1.175 billion yuan through convertible bonds to enhance its testing capabilities and increase revenue from high-end services [3]. Financial Data Summary - The company’s projected revenues for 2025 and 2026 are 1.369 billion yuan and 1.743 billion yuan, respectively, with expected net profits of 196 million yuan and 280 million yuan [5][11]. - The EBITDA for 2025 is estimated at 618 million yuan, with a projected growth rate of 27.14% [5][11]. - The company’s earnings per share (EPS) is expected to reach 1.72 yuan in 2025, with a price-to-earnings (P/E) ratio of 40.18 [5][11].

Investment Rating - Industry Rating: Outperform the Market (maintained rating) [7] Core Viewpoints - In Q1 2025, commercial banks' net profit growth year-on-year was -2.32%, a decrease of 4 basis points compared to the end of 2024, although the profitability of state-owned banks and urban/rural commercial banks showed improvement [12][10] - The asset expansion of commercial banks remained stable, with total assets growing by 7.20% year-on-year in Q1 2025, slightly slowing down by 3 basis points compared to the end of last year [2][17] - The net interest margin (NIM) for commercial banks was recorded at 1.43% in Q1 2025, down 9 basis points from the end of 2024, with expectations for stabilization in Q2 2025 due to new monetary policy measures [3][20] - Asset quality remained robust, with a non-performing loan (NPL) ratio of 1.51% in Q1 2025, a slight increase of 1 basis point from the end of 2024, and a provision coverage ratio of 208%, indicating ample buffer above the regulatory requirement [4][23] - The capital adequacy ratios for commercial banks showed a decline, with the overall capital adequacy ratio at 15.28%, down 45 basis points from the previous quarter, indicating increased capital consumption due to credit expansion [5][26] Summary by Sections 1. Profitability - In Q1 2025, commercial banks' net profit totaled 656.8 billion yuan, a year-on-year decrease of 200 million yuan, with state-owned banks showing a profit increase of 15.8 billion yuan [12][10] 2. Asset Expansion and Credit Performance - Total assets of commercial banks reached approximately 394 trillion yuan, with a year-on-year growth of 7.20% in Q1 2025 [17] - The loan balance increased by 9.11 trillion yuan in Q1 2025, with a year-on-year growth rate of 7.33% [18] 3. Net Interest Margin - The NIM for state-owned banks, joint-stock banks, urban commercial banks, and rural commercial banks were 1.33%, 1.56%, 1.37%, and 1.58% respectively, with expectations for stabilization in Q2 2025 [20][21] 4. Asset Quality - The NPL ratio for state-owned banks, joint-stock banks, urban commercial banks, and rural commercial banks were 1.22%, 1.23%, 1.79%, and 2.86% respectively, indicating overall stable asset quality [23] 5. Capital Adequacy - The risk-weighted assets of commercial banks reached 214 trillion yuan, with capital adequacy ratios showing a decline across various types of banks [26][5]